Drug Profile
Lung cancer vaccine - GSK
Latest Information Update: 16 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 17 Sep 2003 Phase-I clinical trials in Non-small cell lung cancer in USA (IM, Injection)
- 30 Jul 2002 This vaccine is still in active development
- 17 Jun 1999 Preclinical development for Lung cancer in USA (Unknown route)